First, the major limitation is the retrospective nature of the study with the two groups of patients enrolled in two different periods: pre- and post-SGLT2 prescription and reimbursement for HF, even though we conducted propensity score-matched analysis to minimize the impact of confounding factors. This evidence concerns the gene SLC5A2 and hydrops fetalis.